New research into benefits of Prilactone for CHF
A new publication into the benefits of spironolactone (Prilactone - CEVA Animal Health) has supported its use as part of first-line therapy for the treatment of dogs with congestive heart failure caused by mitral heart disease, according to CEVA. The double-blind placebo-controlled study 1 involved 212 dogs on either spironolactone or a placebo, in addition to conventional therapy including an ACE inhibitor and furosemide. It revealed that over a 15 month period 25.5% of dogs either died, were euthanased or severely worsened in the placebo group compared to 10.8% in the spironolactone group. This...
As a member, you can connect with other vets, get full access to our comprehensive diary for the profession, advertise and browse jobs for veterinary surgeons, participate in various special interest groups and associations, and much more...